MedTrace Logo

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

NCT00390676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2010-12-28

No results posted yet for this study

Summary

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.

Conditions

  • Neoplasms

Interventions

DRUG

ADH -1 and carboplatin

DRUG

ADH -1 and docetaxel

DRUG

ADH -1 and capecitabine

Sponsors & Collaborators

  • US Oncology Research

    collaborator INDUSTRY

  • Adherex Technologies, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390676 on ClinicalTrials.gov